An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer

Breast Cancer, Colorectal Cancer, Gastric Cancer Clinical Trial

Official title: A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer

Status Completed

Clinical Trial Summary

This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Breast Cancer, Colorectal Cancer, Gastric Cancer
• Breast Neoplasms
• Colorectal Neoplasms
• Stomach Neoplasms

• NCT number: NCT01664494
• Study type: Observational
• Source: Hoffmann-La Roche
• Status: Completed
• Phase: N/A
• Start date: April 2010
• Completion date: July 2012